Tango Therapeutics Stock Investor Sentiment

TNGX Stock  USD 3.10  0.21  6.34%   
Slightly above 74% of Tango Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Tango Therapeutics suggests that many traders are alarmed. Tango Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Tango Therapeutics' earnings reports, geopolitical events, and overall market trends.
  

Tango Therapeutics Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Tango Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over six months ago at investing.com         
Tango Therapeutics shares target cut by H.C. Wainwright, highlights key drug
Investing News at Macroaxis
over six months ago at www.macroaxis.com         
Disposition of tradable shares by Boxer Capital, Llc of Tango Therapeutics subject to Rule 16b-3
Macroaxis News
over six months ago at investing.com         
Tango Therapeutics halts TNG348 trial due to toxicity
Investing News at Macroaxis
over six months ago at businesswire.com         
Tango Therapeutics Announces Discontinuation of TNG348 Program
businesswire News
over six months ago at seekingalpha.com         
Tango Therapeutics to discontinue development of TNG348 program
seekingalpha News
over six months ago at finance.yahoo.com         
Tango Therapeutics Shuts Early-Stage Cancer Study Due To Liver Toxicity
Yahoo News
over six months ago at news.google.com         
Tango Therapeutics, Inc. Reports Q2 Loss, Tops Revenue Estimates - Yahoo Canada Shine On
Google News at Macroaxis
over six months ago at news.google.com         
Tango Therapeutics Shares Down 3.7 percent - MarketBeat
Google News at Macroaxis
over six months ago at news.google.com         
symbol Stock Quote Price and Forecast - CNN
Google News at Macroaxis
over six months ago at news.google.com         
Tango Therapeutics Announces 80 million Private Placement Financing - Quantisnow
Google News at Macroaxis
over six months ago at news.google.com         
Tango Therapeutics Rating Reiterated by HC Wainwright - Defense World
Google News at Macroaxis
over six months ago at news.google.com         
The past year for Tango Therapeutics investors has not been profitable - Yahoo Canada Shine On
Google News at Macroaxis
over six months ago at news.google.com         
100,691 Shares in Tango Therapeutics, Inc. Acquired by Fisher Asset Management LLC - MarketBeat
Google News at Macroaxis
over six months ago at news.google.com         
Tango Therapeutics reports Q1 EPS , consensus - TipRanks.com - TipRanks
Google News at Macroaxis
over six months ago at finance.yahoo.com         
Tango Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights
Yahoo News
Far too much social signal, news, headlines, and media speculation about Tango Therapeutics that are available to investors today. That information is available publicly through Tango media outlets and privately through word of mouth or via Tango internal channels. However, regardless of the origin, that massive amount of Tango data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Tango Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Tango Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Tango Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Tango Therapeutics alpha.

Tango Therapeutics Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Tango Therapeutics Shares Down 3 percent - MarketBeat
09/23/2024
2
Insider Trading
10/10/2024
3
Disposition of 625000 shares by Boxer Capital Management, Llc of Tango Therapeutics at 7.05 subject to Rule 16b-3
10/21/2024
4
Disposition of 250000 shares by Boxer Capital Management, Llc of Tango Therapeutics at 6.78 subject to Rule 16b-3
10/22/2024
5
Disposition of 633000 shares by Boxer Capital Management, Llc of Tango Therapeutics at 6.87 subject to Rule 16b-3
10/25/2024
6
Acquisition by Peters Malte of 6250 shares of Tango Therapeutics subject to Rule 16b-3
11/01/2024
7
Tango Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights
11/06/2024
8
Disposition of 1143124 shares by Ecor1 Capital, Llc of Tango Therapeutics at 2.9171 subject to Rule 16b-3
11/07/2024
9
Tango Therapeutics sees 9.67m stock sale by Boxer Capital
11/08/2024
10
Tango Therapeutics SWOT analysis stock outlook amid PRMT5 inhibitor progress
11/13/2024
11
Acquisition by Rothenberg Mace of 10000 shares of Tango Therapeutics at 3.62 subject to Rule 16b-3
11/14/2024
12
Acquisition by Rothenberg Mace of 10000 shares of Tango Therapeutics at 3.78 subject to Rule 16b-3
11/18/2024
13
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635
12/03/2024
14
Is Tango Therapeutics In A Good Position To Invest In Growth
12/05/2024

Additional Tools for Tango Stock Analysis

When running Tango Therapeutics' price analysis, check to measure Tango Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tango Therapeutics is operating at the current time. Most of Tango Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tango Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tango Therapeutics' price. Additionally, you may evaluate how the addition of Tango Therapeutics to your portfolios can decrease your overall portfolio volatility.